Navigation Links
Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
Date:9/26/2007

CAMBRIDGE, Mass., and BERLIN, Sept. 26 /PRNewswire-FirstCall/ -- Genzyme Corporation (Nasdaq: GENZ) and Bayer Schering Pharma AG, Germany today announced that the first patient has been treated in the first of two planned Phase 3 trials examining the safety and efficacy of alemtuzumab for the treatment of multiple sclerosis (MS).

The CARE-MS I trial (Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis), a randomized, rater-blinded study, will compare alemtuzumab to Rebif(R) (interferon beta-1a) in patients with relapsing- remitting multiple sclerosis (MS). Alemtuzumab will be given in two annual cycles; Rebif will be administered three times per week. The CARE-MS I study will include patients who have been diagnosed with relapsing-remitting MS but who have not yet begun treatment with any MS drug. CARE-MS II is scheduled to begin soon and will enroll patients who have continued to experience relapse episodes while on currently available disease-modifying therapies.

Initiation of this Phase 3 program follows the successful completion of the initial treatment period in the Phase 2 trial. Interim results from the Phase 2 trial indicated that alemtuzumab-treated patients experienced a statistically significant reduction compared with Rebif-treated patients in the risk for sustained accumulation of disability and the risk for relapse for 24 months. Results of the primary outcomes from this trial at 36 months are expected to be presented on Oct. 14 by Professor Alastair Compston during the Charcot Award lecture at the annual meeting of the European Committee for Treatment and Research in Multiple Sclerosis, in Prague.

The CARE-MS I study will enroll up to 525 patients at approximately 60 med
'/>"/>

SOURCE Genzyme Corporation; Bayer Schering Pharma AG
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
2. Genzyme Announces Results of Clinical Trial of Hylastan
3. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
4. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
5. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
6. Genzyme Announces Successful Completion of Study Investigating Sevelamer Carbonate in Patients With Chronic Kidney Disease
7. Schering-Plough Announces Hepatitis C Data Presentations at Digestive Disease Week (DDW) 2007 Annual Meeting
8. Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
9. Schering-Plough Announces Presentation of Phase II Trial Results for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual Meeting of The American College of Cardiology/i2 Summit
10. Sygnis Pharma AG announces date for presentation of clinical results
11. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... 26, 2015  LabStyle Innovations Corp. (DRIO), ... announced today that in partnership with ... Healthcare, it has launched  the comprehensive Dario™ ... advanced Telecare unit (MOMA). The Dario™ is ... enables remote treatment for diabetes aiming to ...
(Date:5/26/2015)... Mass. , May 26, 2015 Boston Scientific ... the Goldman Sachs 36 th Annual Global Healthcare Conference ... Dan Brennan , executive vice ... vice president, Investor Relations, will participate in a 35-minute question ... beginning at approximately 10 a.m. PT. A live ...
(Date:5/26/2015)... Mast Therapeutics, Inc. (NYSE ... molecular adhesion and sealant technology (MAST) platform to ... failure, and arterial disease, today reported that it ... study of vepoloxamer (MST-188) in sickle cell disease, ... patients who have completed the Company,s Phase 3 ...
Breaking Medicine Technology:LabStyle Innovations and Maccabi Healthcare Launch Dario Platform for Remote Treatment of Diabetes in Israel 2LabStyle Innovations and Maccabi Healthcare Launch Dario Platform for Remote Treatment of Diabetes in Israel 3LabStyle Innovations and Maccabi Healthcare Launch Dario Platform for Remote Treatment of Diabetes in Israel 4Boston Scientific To Participate In The Goldman Sachs 36th Annual Global Healthcare Conference 2Mast Therapeutics Announces Initiation Of EPIC-E Study 2Mast Therapeutics Announces Initiation Of EPIC-E Study 3Mast Therapeutics Announces Initiation Of EPIC-E Study 4Mast Therapeutics Announces Initiation Of EPIC-E Study 5
... , SANTA MONICA, Calif. , March 18 ... of Derycz Scientific, Inc., (OTC Bulletin Board: DYSC), a ... the flow of information from content publishers to enterprise ... journals Pharmaceutical Manufacturing and Genetic Engineering ...
... , CINCINNATI , March 17 Kendle (Nasdaq: ... announced Dr. Ross Horsburgh , Vice President, Asia/Pacific ... March 17-18, 2010 at the Raffles City Convention Centre ... in Asia ," is scheduled for March 18 ...
Cached Medicine Technology:Derycz Scientific Featured in Pharmaceutical Manufacturing and Genetic Engineering & Biotechnology News 2Derycz Scientific Featured in Pharmaceutical Manufacturing and Genetic Engineering & Biotechnology News 3Derycz Scientific Featured in Pharmaceutical Manufacturing and Genetic Engineering & Biotechnology News 4Kendle Executive to Share Insights at World Pharma Trials Asia 2010 2Kendle Executive to Share Insights at World Pharma Trials Asia 2010 3
(Date:5/26/2015)... NC (PRWEB) May 26, 2015 ... compliance solutions for the health and human services market, ... to meet demand. After strong attendance and participation in ... groups, and give their annual user conference an exciting ... Relias customers to come together and discuss best practices, ...
(Date:5/26/2015)... MD (PRWEB) May 26, 2015 ... marijuana. According to an article published by ... synthetic marijuana (dubbed K2, Spice, and black mamba) ... composition of these synthetic substances make it nearly ... confirm patients’ use of the substance due to ...
(Date:5/26/2015)... 26, 2015 Pasadena porcelain veneers ... dental cleanings with cosmetic treatments. Cosmetic dentistry is becoming ... Dentistry , “We are committed to providing you with ... outstanding customer service and a smile of a lifetime ... your smiles but to change your life,” explains Dr. ...
(Date:5/26/2015)... Indosoft, Inc ., developer of ... DMi Partners contact center to Q-Suite 5.8 ... Indosoft's contact center ACD system to drop Asterisk 1.4 ... such trunk features as diversion headers, added Lyra support ... upgrades to warm transfers to improve information ...
(Date:5/26/2015)... May 26, 2015 National Prevention Week ... year. It is supported by the Substance Abuse ... raising public awareness of, and action about, substance abuse ... organizations and coalitions are encouraged to join in promoting ... and related issues, and in building community partnerships. , ...
Breaking Medicine News(10 mins):Health News:Relias Learning Expands User Groups and Industry Influence 2Health News:Relias Learning Expands User Groups and Industry Influence 3Health News:Synthetic Cannabinoids Can Cause Psychotic Episodes; Doctors at a Loss for Treatment 2Health News:Synthetic Cannabinoids Can Cause Psychotic Episodes; Doctors at a Loss for Treatment 3Health News:Pasadena Porcelain Veneers Expert, Marine Martirosyan DDS, is Now Offering Complimentary Dental Cleaning with Cosmetic Treatments 2Health News:DMi Partners Upgrades to Indosoft Q-Suite 5.8 2Health News:DMi Partners Upgrades to Indosoft Q-Suite 5.8 3Health News:Narconon Arrowhead Takes Part in National Prevention Week 2Health News:Narconon Arrowhead Takes Part in National Prevention Week 3
... ... Speaks at Gladys B. Jacobs Manor, in North Central Philadelphia , ... Philadelphia, PA (Vocus) October 28, 2009 ... Latina ever appointed to that position, recently spoke at the Original Richard Allen Committee’s ...
... /PRNewswire/ - LPBP Inc. (the "Company") announces a ... related to the per share dividend payable on ... dividend on the Class B Non-Voting shares should ... A Common shares of $0.0099 per share remains ...
... Oct. 28 In response to rising suicide and ... dedicated to supporting marriages and families, will present its ... to military couples in Milwaukee from Nov. 6 - 8 ... Weekend to Remember is a marriage getaway aimed ...
... California religious and community leaders, who have witnessed first ... well as the homeless, sick and mentally ill, gathered ... legalizing marijuana sales and use in California. , ... numerous faiths and religious denominations, were joined by community ...
... in tissue damage caused by smoking , WEDNESDAY, Oct. ... therapy for injured lungs that were previously rejected for ... transplant, researchers say. , Successful transplants require healthy lungs, ... highly inflamed and only mildly functional, which means many ...
... 28 If we get a boo-boo, we might know to ... kiss it and make it all better. But, what if ... us who aren,t prepared for dental emergencies can quickly get back ... Company at: , http://inr.mediaseed.tv/oneClip_C/?feed=Ss8P5Rb1iQulYDAELUR0M_kpwKp_6YSM , Medialink ...
Cached Medicine News:Health News:Head of PA Department of Aging Speaks at the Richard Allen Committee's 17th Annual Senior Citizen's Event 2Health News:FamilyLife Supports Military Marriages in Milwaukee 2Health News:Faith-Based Leaders and Community Activists Converge on State Capitol to Oppose Legalized Marijuana 2Health News:Faith-Based Leaders and Community Activists Converge on State Capitol to Oppose Legalized Marijuana 3Health News:Repairing Injured Lungs May Boost Organ Donations 2
... Cell-Chex is a spinal and body fluid ... When stained in the same manner as ... can be differentiated. The two-level control is ... white blood cell differential, as well as ...
... is a gene expression ... the risk of metastasis ... It is based on ... the Netherlands Cancer Institute ...
Antelys Peek Lumbar Technologies provides a range of varied heights and angles to correct lumbar lordosis and the associated sagital balance....
Abiomed introduces its new intra-aortic balloon (IAB); an easy-to-insert, minimally invasive technology designed to enhance blood flow to the heart and other organs for patients with diminished heart...
Medicine Products: